669P - The role of adjuvant chemotherapy for elderly patients with gastric cancer after a gastrectomy in Korea

Date 29 September 2014
Event ESMO 2014
Session Poster Display session
Topics Anti-Cancer Agents & Biologic Therapy
Gastric Cancer
Geriatric Oncology
Presenter Jae-Cheol Jo
Citation Annals of Oncology (2014) 25 (suppl_4): iv210-iv253. 10.1093/annonc/mdu334
Authors J. Jo1, J.H. Baek1, S. Koh1, Y.J. Min1, H.R. Cho2, G.Y. Kim2
  • 1Hematology-oncology, Ulsan University Hospital, 682-714 - Ulsan/KR
  • 2Surgery, Ulsan University Hospital, 682-714 - Ulsan/KR

Abstract

Aim

Adjuvant chemotherapy is recommended for gastric cancer after a gastrectomy with D2 dissection. However, its survival benefit in elderly patients is unclear. Here, we investigated the use of adjuvant chemotherapy in patients ≥70 years old with stage II or III gastric cancer to identify its impact on survival.

Methods

Patients ≥70 years old diagnosed with stage II or III gastric cancer at Ulsan University Hospital from 2008–2012 were identified. A retrospective analysis of electronic and paper patient records was performed to identify baseline characteristics, chemotherapy used, toxicity, and survival.

Results

From 2008–2012, 277 patients ≥70 years old underwent gastrectomy with D2 dissection. Of these patients, 94 were pathologically diagnosed with stage II or III gastric cancer; 55 of these patients (58.5 %) received adjuvant chemotherapy and 39 received regular check-ups without chemotherapy. Fluoropyrimidine-alone regimens, including TS-1 (n = 26) and didox (n = 22), were more commonly used than fluoropyrimidine-platinum combination regimens (n = 7). With a median follow-up of 30.9 (range, 0.8–65.5) months, the median relapse-free survival of patients with adjuvant chemotherapy or regular follow-up only was 35.5 and 20.4 months, respectively (p = 0.030). Multivariate analysis revealed that adjuvant chemotherapy is associated with longer relapse-free survival (hazard ratio, 0.50; 95 % confidence interval, 0.27–0.96). There was a trend toward an improved overall survival in the adjuvant chemotherapy group compared with the follow-up only group (p = 0.242).

Conclusions

Although well-designed prospective studies are required, adjuvant chemotherapy may confer a potential survival benefit in elderly patients (aged 70 or older) with stage II or III gastric cancer after a gastrectomy with D2 dissection.

Disclosure

All authors have declared no conflicts of interest.